CD79A and rheumatoid arthritis: In a group of 30 patients with RA, those with a clinical response to abatacept therapy experienced significant decreases in levels of IgG, IgA, IgM, and post-switch memory B cells and normalization of free light chains at 6 months and decreases in memory B cell subsets at 12 months [28•].